QLT Completes Sale of Visudyne to Valeant Pharmaceuticals
QLT Inc. announced that it has completed the sale
of the company’s Visudyne (verteporfin injection) business
to Valeant Pharmaceuticals International Inc. for
$112.5 million plus contingency payments, according to
a company news release.
Valeant will pay $50 million of the initial purchase
price for the right to r...